SAN DIEGO--(BUSINESS WIRE)--
AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that Paul C. Grint, M.D., Chief Executive Officer, will present a company overview at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, Sept. 11.
“We are developing our proprietary bacteriophage technology using expanded access regulatory guidelines established by the FDA in the United States and the TGA in Australia,” said Dr. Grint. “Our lead bacteriophage candidates have the potential to treat patients with serious or life-threatening multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa infections, both included on the WHO’s 2017 Priority Pathogens List. We expect the data from these expanded access cases to support the selection of indications for further clinical development in the first half of 2018 and, in consultation with the FDA, TGA and other regulatory agencies, define the potential path to regulatory approval.”
Event Details and Webcast Information
Event: Rodman & Renshaw 19th Annual Global Investment
Conference
Date: Monday, Sept. 11, 2017
Time: 3:25 p.m. EDT /
12:25 p.m. PDT
Webcast: investor.ampliphibio.com/events-and-presentations
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi’s lead product candidates target multidrug-resistant S. aureus and P. aeruginosa, which are included on the WHO’s 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit www.ampliphibio.com.
Forward Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation: statements about the potential benefits of phage therapy and the potential use of bacteriophages to treat bacterial infections, including infections that do not respond to antibiotics; AmpliPhi’s development of bacteriophage-based therapies; and AmpliPhi’s strategy for developing its lead therapeutic candidates through treatment of individual patients under compassionate-use guidelines, including the expected selection of indications in the first half of 2018; and other potential benefits expected from this strategy. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in these forward-looking statements are risks and uncertainties associated with AmpliPhi’s business and financial condition and the other risks and uncertainties described in AmpliPhi’s Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC, and AmpliPhi’s subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and AmpliPhi undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005302/en/
